IASO Biotherapeutics ("IASO Bio") and Umoja Biopharma, Inc. ("Umoja") have recently announced a strategic collaboration to advance the development and commercialization of innovative cell and gene therapies. Specializing in cell therapies and antibody products, IASO Bio will gain exclusive access to Umoja's rapamycin-activated cytokine receptor (RACR™) platform, a synthetic cytokine receptor technology. This collaboration will focus on the development of two ex vivo induced pluripotent stem cell (iPSC)-derived chimeric antigen receptor (CAR)-bearing cell therapies.
IASO Bio will undertake responsibilities for worldwide product development, manufacturing, regulatory processes, and commercialization for both ex vivo products. In return, Umoja will be granted exclusive rights to CAR cassettes for two targets, enabling the advancement of two in vivo product candidates utilizing VivoVec™, Umoja's proprietary lentiviral in vivo gene delivery technology. Umoja will handle product development, manufacturing, regulatory matters, and commercialization outside of Greater China, while IASO Bio will manage these aspects within the Greater China territory. Both parties will be entitled to customary development and sales milestones as well as royalties related to the collaborations.
The collaboration aims to propel the development of off-the-shelf cell and gene therapies, leveraging innovative scientific advancements with applications in oncology and immunology. Alan Fu, Chief Financial Officer of IASO Bio, expressed excitement about the collaboration, highlighting the potential of combining Umoja's RACR platform with IASO's validated CAR constructs to deliver novel allogeneic treatments globally. Umoja's Chief Operating and Chief Business Officer, David Fontana, PhD, emphasized the shared commitment to making cell therapies more accessible, stating that the collaboration goes beyond traditional approaches to maximize the potential of CAR-T cell therapies. The incorporation of IASO's CARs with Umoja's VivoVec technology holds the promise of expanding the reach of in vivo gene delivery technology into new indications and offering additional options for patients in need.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!